Zhang Kai Yu, Imazeki Fumio, Fukai Kenichi, Arai Makoto, Kanda Tatsuo, Mikata Rintaro, Yokosuka Osamu
Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ward, Chiba City, Chiba 260-8670, Japan.
Cancer Sci. 2007 Dec;98(12):1921-9. doi: 10.1111/j.1349-7006.2007.00609.x. Epub 2007 Sep 19.
Hepatitis B virus (HBV) genotype C and the basic core promoter (BCP) mutations were reported to be associated with the development of hepatocellular carcinoma (HCC). In this study the full sequences of HBV genomes were analyzed in order to find the other predictors of HCC development. We determined the full sequences of HBV genomes in 24 genotype C carriers who developed HCC (HCC group) at the beginning of follow-up and at the time of HCC diagnosis, and 20 patients who did not develop HCC (non-HCC group) served as a control. The number of nucleotide and amino acid substitutions in most regions was higher in the HCC group than in the non-HCC group, and the following substitutions and deletions were found more frequently in the HCC group than in the non-HCC group: G1317A and T1341C/A/G in the X promoter region were detected in 13 and six of the HCC cases, four and none of the non-HCC cases, respectively; and pre-S2 deletion was detected in eight HCC and none of the non-HCC cases. Compared with the wild type X promoter, the mutant type X promoters, M1 (G1317A), M2 (T1341C), and M4 (T1341G) showed increases in activity of 2.3, 3.8, and 1.4 times, respectively, in HepG2 cells. Substitutions and deletion of nucleotides of the HBV genome, especially the pre-S2 deletion and G1317A and T1341C/A/G mutations may be useful markers for predicting the development of HCC.
据报道,乙型肝炎病毒(HBV)基因C型和基本核心启动子(BCP)突变与肝细胞癌(HCC)的发生有关。在本研究中,对HBV基因组的完整序列进行了分析,以寻找HCC发生的其他预测指标。我们测定了24例在随访开始时和HCC诊断时发生HCC的基因C型携带者(HCC组)以及20例未发生HCC的患者(非HCC组)作为对照的HBV基因组完整序列。HCC组大多数区域的核苷酸和氨基酸替代数量高于非HCC组,并且以下替代和缺失在HCC组中比在非HCC组中更频繁地被发现:X启动子区域的G1317A和T1341C/A/G分别在13例和6例HCC病例中检测到,在4例和0例非HCC病例中检测到;并且在8例HCC病例中检测到前S2缺失,在非HCC病例中未检测到。与野生型X启动子相比,突变型X启动子M1(G1317A)、M2(T1341C)和M4(T1341G)在HepG2细胞中的活性分别增加了2.3倍、3.8倍和1.4倍。HBV基因组核苷酸的替代和缺失,尤其是前S2缺失以及G1317A和T1341C/A/G突变可能是预测HCC发生的有用标志物。